These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
133 related items for PubMed ID: 8331476
21. Respiration and oxidative phosphorylation in the apicomplexan parasite Toxoplasma gondii. Vercesi AE, Rodrigues CO, Uyemura SA, Zhong L, Moreno SN. J Biol Chem; 1998 Nov 20; 273(47):31040-7. PubMed ID: 9813002 [Abstract] [Full Text] [Related]
22. Lack of mitochondrial MutS homolog 1 in Toxoplasma gondii disrupts maintenance and fidelity of mitochondrial DNA and reveals metabolic plasticity. Garbuz T, Arrizabalaga G. PLoS One; 2017 Nov 20; 12(11):e0188040. PubMed ID: 29141004 [Abstract] [Full Text] [Related]
23. Quinonic derivatives active against Toxoplasma gondii. Sarciron ME, Nebois P, Pautet F, Pétavy AF, Fillion H, Walchshofer N. Parasitol Res; 2002 Nov 20; 88(11):969-71. PubMed ID: 12375161 [Abstract] [Full Text] [Related]
24. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii. Romand S, Della Bruna C, Farinotti R, Derouin F. Antimicrob Agents Chemother; 1996 Sep 20; 40(9):2015-20. PubMed ID: 8878573 [Abstract] [Full Text] [Related]
25. Characterization of a mutant of Toxoplasma gondii resistant to aphidicolin. Pfefferkorn ER. J Protozool; 1984 May 20; 31(2):306-10. PubMed ID: 6206226 [Abstract] [Full Text] [Related]
28. Artemisinin-resistant mutants of Toxoplasma gondii have altered calcium homeostasis. Nagamune K, Moreno SN, Sibley LD. Antimicrob Agents Chemother; 2007 Nov 20; 51(11):3816-23. PubMed ID: 17698618 [Abstract] [Full Text] [Related]
29. Toxoplasma gondii: susceptibility and development of resistance to anticoccidial drugs in vitro. Ricketts AP, Pfefferkorn ER. Antimicrob Agents Chemother; 1993 Nov 20; 37(11):2358-63. PubMed ID: 8285619 [Abstract] [Full Text] [Related]
30. Toxoplasma gondii: the biochemical basis of resistance to emimycin. Pfefferkorn ER, Eckel ME, McAdams E. Exp Parasitol; 1989 Aug 20; 69(2):129-39. PubMed ID: 2526747 [Abstract] [Full Text] [Related]
31. Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations. Ling Y, Sahota G, Odeh S, Chan JM, Araujo FG, Moreno SN, Oldfield E. J Med Chem; 2005 May 05; 48(9):3130-40. PubMed ID: 15857119 [Abstract] [Full Text] [Related]
32. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Schöler N, Krause K, Kayser O, Müller RH, Borner K, Hahn H, Liesenfeld O. Antimicrob Agents Chemother; 2001 Jun 05; 45(6):1771-9. PubMed ID: 11353624 [Abstract] [Full Text] [Related]
34. Toxoplasma gondii: in vitro and in vivo activities of the hydroxynaphthoquinone 2-hydroxy-3-(1'-propen-3-phenyl)-1,4-naphthoquinone alone or combined with sulfadiazine. Ferreira RA, Oliveira AB, Ribeiro MF, Tafuri WL, Vitor RW. Exp Parasitol; 2006 Jun 05; 113(2):125-9. PubMed ID: 16458300 [Abstract] [Full Text] [Related]
37. The biochemical basis for resistance to adenine arabinoside in a mutant of Toxoplasma gondii. Pfefferkorn ER, Pfefferkorn LC. J Parasitol; 1978 Jun 05; 64(3):486-92. PubMed ID: 207846 [Abstract] [Full Text] [Related]